An official website of the United States government
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Mepolizumab (Nucala) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Nov.
| Drug | mepolizumab (Nucala) |
|---|---|
| Indication | For the add-on maintenance treatment of adult patients with severe eosinophilic asthma who:
|
| Reimbursement request | For the treatment of adult patients (≥ 18 years) with severe eosinophilic asthma (≥ 150 cells/mcL at treatment initiation or ≥ 300 cells/mcL in past 12 months) whose symptoms are inadequately controlled with high-dose inhaled corticosteroids and an additional asthma controller(s), and who have either experienced ≥ 2 exacerbations in the past 12 months or have dependency on systemic corticosteroids. |
| Dosage form(s) | Lyophilized powder for subcutaneous injection, 100 mg/mL |
| NOC date | 3 December 2015 |
| Manufacturer | GlaxoSmithKline Inc. |
Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
Your browsing activity is empty.
Activity recording is turned off.
See more...
